ROUND ROCK, Texas — Benuvia Operations LLC, a global contract development and manufacturing organization, signed an agreement with Trait Biosciences to accelerate the commercialization of new-to-market water-soluble cannabinoids.
Under the terms of the agreement, Benuvia will scale up and qualify the manufacturability of Trait’s lead synthetic tetrahydrocannabidiol (H4CBD) derivatives. In addition, Benuvia and Trait plan to expand the collaboration to include the manufacturability and production of additional cannabinoid derivatives.
“Trait has established a solid reputation in the cannabinoid industry, and we are pleased to partner with their team on this project,” said Terry Novak, CEO of Benuvia. “We have had a strong start to the year at Benuvia, with growing demand for early-stage development research. We look forward to being the preferred partner for companies seeking a unified services platform to support their journey from pre-clinical development to commercial launch and supply.”
“Scaling up at Benuvia enables us to further our commercial plans for our water-soluble cannabinoids and enables our customers to qualify our factory-produced water-soluble cannabinoids into their end-use products. We are excited to collaborate with the Benuvia team on this important initiative for Trait,” said Dr. Hanny Kanafani, president and COO of Trait Biosciences.
About Trait Biosciences
Trait Biosciences is a science-focused research organization focused on developing truly water-soluble hemp-derived cannabinoids, leveraging biotechnology and chemical synthesis processes, and qualifying manufacturability, thereby providing our customers with unique and differentiated ingredients for their formulation into a variety of consumer products.
About Benuvia Operations, LLC
Benuvia Operations LLC is a global Contract Development and Manufacturing Organization (CDMO) that helps pharmaceutical and biotech companies deliver life-changing therapies to patients in need. The company provides end-to-end development and manufacturing services for Active Pharmaceutical Ingredients (APIs) and finished dosage products and has extensive experience with cannabinoids, psychedelics, and other controlled substances. Benuvia operates an 83,000 square foot manufacturing facility in Round Rock, Texas that can produce Schedule I-V compounds, offering comprehensive solutions for companies throughout the entire drug development lifecycle — from API synthesis and clinical trial supply to commercial production.
